BioCardia Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCardia in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BioCardia stock.
View analyst ratings for BioCardia or view top-rated stocks.

Wall Street analysts have given BioCardia a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioCardia wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

BioCardia saw a increase in short interest in March. As of March 31st, there was short interest totaling 458,300 shares, an increase of 68.4% from the March 15th total of 272,200 shares. Based on an average daily trading volume, of 295,700 shares, the days-to-cover ratio is currently 1.5 days.
View BioCardia's Short Interest.

BioCardia is scheduled to release its next quarterly earnings announcement on Friday, May 21st 2021.
View our earnings forecast for BioCardia.

BioCardia, Inc. (NASDAQ:BCDA) posted its quarterly earnings data on Monday, March, 29th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.30) by $0.15. BioCardia had a negative net margin of 5,103.95% and a negative trailing twelve-month return on equity of 496.87%.
View BioCardia's earnings history.

BioCardia's stock was trading at $3.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BCDA shares have increased by 2.5% and is now trading at $3.68.
View which stocks have been most impacted by COVID-19.

Shares of BioCardia reverse split on Friday, November 3rd 2017. The 1-12 reverse split was announced on Thursday, November 2nd 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 2nd 2017. An investor that had 100 shares of BioCardia stock prior to the reverse split would have 8 shares after the split.

3 equities research analysts have issued 12 month target prices for BioCardia's stock. Their forecasts range from $7.00 to $11.50. On average, they anticipate BioCardia's stock price to reach $9.25 in the next year. This suggests a possible upside of 151.4% from the stock's current price.
View analysts' price targets for BioCardia or view top-rated stocks among Wall Street analysts.

Some companies that are related to BioCardia include CASI Pharmaceuticals (CASI), ADMA Biologics (ADMA), INmune Bio (INMB), Genfit (GNFT), LogicBio Therapeutics (LOGC), Gamida Cell (GMDA), Voyager Therapeutics (VYGR), Fennec Pharmaceuticals (FENC), Applied Genetic Technologies (AGTC), Protara Therapeutics (TARA), Axcella Health (AXLA), X4 Pharmaceuticals (XFOR), ERYTECH Pharma (ERYP), BiomX (PHGE) and Champions Oncology (CSBR).
View all of BCDA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCardia investors own include Arotech (ARTX), CytoDyn (CYDY), (SAND), China Gold International Resources (CGG), BioSolar (BSRC), Blink Charging (BLNK), Aurcana Silver (AUNFF), (ANIX), American Manganese (AMY) and (ALT).

(BCDA) raised $51 million in an initial public offering on the week of July 20th 2015. The company issued 3,900,000 shares at $12.00-$14.00 per share. Cantor Fitzgerald & Co. acted as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers.

BioCardia trades on the NASDAQ under the ticker symbol "BCDA."

Shares of BCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BCDA stock can currently be purchased for approximately $3.68.

BioCardia has a market capitalization of $60.13 million and generates $710,000.00 in revenue each year. The company earns $-14,710,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis.

BioCardia employs 24 workers across the globe.

The official website for BioCardia is www.biocardia.com.

BioCardia is headquartered at 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA, 94070.

BioCardia's mailing address is 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA, 94070. The company can be reached via phone at 650-226-0120 or via email at [email protected]